Baird Financial Group Inc. Has $63.78 Million Stock Holdings in Veeva Systems Inc. $VEEV

Baird Financial Group Inc. trimmed its position in Veeva Systems Inc. (NYSE:VEEV) by 6.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 221,466 shares of the technology company’s stock after selling 15,696 shares during the quarter. Baird Financial Group Inc. owned about 0.14% of Veeva Systems worth $63,778,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Sigma Planning Corp lifted its position in Veeva Systems by 1.2% during the 2nd quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock worth $958,000 after acquiring an additional 39 shares during the last quarter. Keybank National Association OH increased its stake in shares of Veeva Systems by 1.4% in the second quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock worth $889,000 after purchasing an additional 42 shares during the period. Facet Wealth Inc. lifted its position in shares of Veeva Systems by 3.3% during the 2nd quarter. Facet Wealth Inc. now owns 1,342 shares of the technology company’s stock worth $381,000 after purchasing an additional 43 shares during the last quarter. TFB Advisors LLC boosted its stake in Veeva Systems by 1.2% during the 1st quarter. TFB Advisors LLC now owns 3,586 shares of the technology company’s stock valued at $831,000 after purchasing an additional 44 shares during the period. Finally, Triangle Securities Wealth Management grew its holdings in Veeva Systems by 0.8% in the 2nd quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock valued at $1,665,000 after buying an additional 45 shares during the last quarter. 88.20% of the stock is owned by institutional investors.

Veeva Systems Price Performance

Shares of VEEV opened at $242.24 on Friday. The company has a market capitalization of $39.82 billion, a P/E ratio of 47.13, a PEG ratio of 1.79 and a beta of 1.05. Veeva Systems Inc. has a one year low of $201.54 and a one year high of $310.50. The business’s 50 day simple moving average is $281.00 and its 200-day simple moving average is $278.57.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. The firm had revenue of $0.81 million during the quarter, compared to analysts’ expectations of $792.37 million. Veeva Systems had a return on equity of 13.68% and a net margin of 27.93%.The business’s revenue was up 16.0% on a year-over-year basis. During the same period last year, the firm posted $1.75 EPS. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. On average, sell-side analysts anticipate that Veeva Systems Inc. will post 4.35 EPS for the current fiscal year.

Insider Activity at Veeva Systems

In other Veeva Systems news, insider Eleni Nitsa Zuppas sold 6,000 shares of the business’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total value of $1,839,720.00. Following the completion of the transaction, the insider directly owned 25,325 shares of the company’s stock, valued at approximately $7,765,151.50. The trade was a 19.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Thomas D. Schwenger sold 3,350 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the transaction, the insider owned 23,773 shares in the company, valued at $7,132,850.92. The trade was a 12.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 24,665 shares of company stock valued at $7,438,000 over the last ninety days. 10.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

VEEV has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Veeva Systems from a “hold” rating to a “buy” rating in a research note on Friday, November 28th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Veeva Systems in a research report on Monday. Raymond James Financial reissued an “outperform” rating and issued a $340.00 target price (up previously from $310.00) on shares of Veeva Systems in a research note on Thursday, August 28th. William Blair restated an “outperform” rating on shares of Veeva Systems in a research note on Friday, October 17th. Finally, UBS Group decreased their price objective on Veeva Systems from $310.00 to $280.00 and set a “neutral” rating on the stock in a report on Friday, November 21st. Twenty research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $305.88.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.